secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095063
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q2 net loss $31.7M; revenue falls to $0.5M; RMAT designation for lead candidates
--------------------------------------------------------------------------------

- Revenue $0.5M, down from $3.1M in Q2 2023, primarily due to Amgen collaboration timing.
- Net loss $31.7M vs $24.0M in Q2 2023; R&D expenses increased to $26.9M from $21.2M.
- Cash, equivalents, and marketable securities $297.7M (plus $5M restricted); funds into Q4 2026.
- FDA granted RMAT designation for TSC-100 and TSC-101 for AML, ALL, MDS post-HCT.
- On track to report one-year heme data and initial solid tumor data by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017024095063/0000950170-24-095063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017024095063/tcrx-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer